ArticleFrontiers in immunology2025
Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma.
Yuan Yao et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this paperpooled itcites it